CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Covid-19 + patientsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2918 non Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.21

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.21

There is one clinical trial.

Clinical Trials

1 Retrospective Observational Study to Compare the Short, Mid- and Long-term Prognosis and Outcomes of SRAS-CoV-2 Infected Hospitalized Patients With Cardiovascular Disease (CVD) to SARS-CoV-2 Infected Hospitalized Patients Without CVD: The Geneva Covid-19 CVD Study

In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.

NCT04384029 COVID CVD Other: Covid-19 + patients

Primary Outcomes

Description: To compare morbidity during hospital stay in COVID-19+ patients with or without preexisting CVD.

Measure: mobidity discharge

Time: 0 days after hospitalization

Description: To compare morbidity 30 days after hospitalization in COVID-19+ patients with or without preexisting CVD.

Measure: mobidity at 30 days

Time: 30 days after hospitalization

Description: To compare morbidity 1 year after hospitalization stay in COVID-19+ patients with or without preexisting CVD.

Measure: mobidity 1 year after hospitalization

Time: 1 year after hospitalization

Description: To compare mortality during hospital stay in COVID-19+ patients with or without preexisting CVD.

Measure: mortality discharge

Time: 0 days after hospitalization

Description: To comparemortality30 days after hospital stay in COVID-19+ patients with or without preexisting CVD.

Measure: mortality 30 days after hospitalization

Time: 30 days after hospitalization

Description: To compare mortality 1 year after hospital stay in COVID-19+ patients with or without preexisting CVD.

Measure: mortality 1 year after hospitalization

Time: 1 year after hospitalization

Secondary Outcomes

Description: Clinical outcomes according to medication at admission evaluated at hospital discharge

Measure: Clinical outcomes according to medication at admission

Time: 0 days after hospitalization

Description: Clinical outcomes according to medication at admission evaluated 30 days after hospitalization

Measure: Clinical outcomes according to medication at admission

Time: 30 days after hospitalization

Description: 1 year after hospitalization

Measure: Clinical outcomes according to medication at admission

Time: 1 year after hospitalization

Description: Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated after hospital discharge

Measure: Clinical outcomes related to preexisting cardiovascular risk factors at admission

Time: 0 days after hospitalization

Description: Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 30 days after hospital discharge

Measure: Clinical outcomes related to preexisting cardiovascular risk factors at admission

Time: 30 days after hospitalization

Description: Clinical outcomes related to preexisting cardiovascular risk factors at admission evaluated 1 year after hospitalization

Measure: Clinical outcomes related to preexisting cardiovascular risk factors at admission

Time: 1 year after hospitalization

Description: New onset of CVD induced by COVID-19 disease at discharge

Measure: New onset of CVD induced by COVID-19 disease

Time: 0 days after hospitalization

Description: New onset of CVD induced by COVID-19 disease evaluated 30 days after hospitalization

Measure: New onset of CVD induced by COVID-19 disease

Time: 30 days after hospitalization

Description: New onset of CVD induced by COVID-19 disease at discharge evaluated 1 year after hospitalization

Measure: New onset of CVD induced by COVID-19 disease

Time: 1 year after hospitalization

Description: Cost of hospital stay

Measure: Cost of hospital stay

Time: 0 days after hospitalization

Description: Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).

Measure: Clinical follow up at 30 days (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).

Time: 30 days after hospitalization

Description: Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).

Measure: Clinical follow up at 1 year (diagnosis of new cardiac events, such as acute coronary syndromes, heart failure, arrhythmia, myocarditis).

Time: 1 year after hospitalization

No related HPO nodes (Using clinical trials)